In a quiet week for director deals one or two trades stood out, firstly the decision by Albert Manifold, chief executive of building materials firm CRH (CRH), to sell 58,346 shares at €51.48 last week, raising €3 million in proceeds.

CRH’s Dublin-listed shares are up 43% this year, recently hitting a multi-year high of €54, while its London quote is due to cease on 25 September after the firm moves its primary listing to New York.

The firm argues the move to Wall Street ‘will bring increased commercial, operational and acquisition opportunities for our business, further accelerating our successful integrated solutions strategy and delivering even higher levels of profitability, returns and cash for our shareholders’.

FORMER PHARMA EXEC CASHES IN OPTIONS

Meanwhile, former GSK (GSK) executive Dr Hal Barron to exercise some of the nil-cost options from his 2020 pay award and offload them in the market.

Latest Issue

• How to buy tech. Three ways to gain exposure to some of the world’s most innovative companies.
• Plus, how Shares' tips of the year are beating the wider market, what the experts think the second half of the year might hold for markets and how investors are reacting to news of incumbent Joe Biden’s exit from the US presidential race.
• Investment ideas include a luxury car maker and an Asian fund focused on income and you can also read an article from Dame Helena Morrissey on how she juggles parenthood and a busy career.
• Discover what the King’s Speech means for UK stocks and how to save money on holiday.

Barron, who until March 2022 was chief scientific officer and president of R&D (research and development) at GSK, cashed in 155,206 ADS (American depository shares) at an average price of $17.31 to net a comfortable $2.67 million.

After leaving the UK firm in March last year, Barron took on the role of chief executive and chairman at US cellular technology company Altos Labs.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.